Pegfilgrastim
Lung Adenocarcinoma In Situ
Wake Forest University Health Sciencesprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Lung Adenocarcinoma In Situ cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin National Cancer Institute (NCI) | Phase 3 | BBB |
Cis-Diamminedichloroplatinum Ii Barbara Ann Karmanos Cancer Institute | Phase 3 | BB |
Gefitinib National Cancer Institute (NCI) | Phase 3 | BB |
Docetaxel Wake Forest University Health Sciences | Phase 3 | BB |
Etoposide Barbara Ann Karmanos Cancer Institute | Phase 3 | BB |
Cetuximab National Cancer Institute (NCI) | Phase 2 | B |
Bortezomib National Cancer Institute (NCI) | Phase 2 | B |
Cixutumumab National Cancer Institute (NCI) | Phase 2 | CCC |
Same molecule, other indications
Pegfilgrastim is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →